NCT Number: NCT01857466
Ovarian Reserve After Ovarian Hemostasis by Floseal Matrix
Laparoscopy has become the gold standard for the surgical treatment of benign ovarian cysts and is usually performed by stripping the ovarian cyst wall, followed by bleeding control of the ovarian wound ground using bipolar coagulation. However, the hemostasis with bipolar coagulation could result in the damage of ovarian reserve and decrease the response of the ovaries to hormonal stimulation for assisted reproductive technologies. The possible mechanism may contribute to thermal destruction of ovarian follicles by excessive use of bipolar coagulation for hemostasis purposes.
To avoid additional ovarian tissue damage by conventional bipolar coagulation being potentially important ovarian reproductive function, hemostasis using various topical hemostatic agents has introduced to control post-cystectomy ovarian wound bleeding. Among them, FloSeal (Baxter Healthcare Corporation, Deerfield, IL, USA) is a hemostatic matrix sealant composed of a gelatin-based matrix and thrombin solution. On coming into contact with blood after application at a bleeding site, the gelatin particles swell and tamponade bleeding. The bulk of the gelatin matrix-thrombin composite has the effect of slowing blood flow and providing exposure to a high thrombin concentration, thus hastening clot formation. Therefore, it may more suitable for use in post-cystectomy ovarian wound bleeding, where there is superficially pervasive focus of bleeding.
Ovarian reserve is defined as the functional potential of the ovary, which reflects the number and quality of antral follicles left in the ovary, and is correlated with the response to ovarian stimulation using exogenous gonadotropin. Serum anti-Müllerian hormone (AMH) has been accepted as the most reliable and easily measurable marker for postoperative assessment of ovarian reserve.
The investigators conducted a multicenter, large-scale, randomized controlled trial to investigate whether hemostasis by Floseal was superior to that by bipolar coagulation in preserving ovarian reserve by assessing serial AMH levels in patients undergoing laparoscopic ovarian cystectomy for benign ovarian cysts.
Looking for future studies?
Notify MeKey information
Conditions
Age range
18 year–45 year
Sex eligibility
Female
Study type
Interventional
Phase
Phase 3
Primary location
National Health Insurance Service Ilsan Hospital, Goyang, South Korea
Who can participate
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
- age between 18 and 45 years
- maximum diameter of the cyst between 3 and 10 cm
- regular menstrual bleeding (defined as cycle length less than 21 or more than 45 days)
- appropriate medical status for laparoscopic surgery (American Society of Anesthesiologists Physical Status classification 1 or 2).
Exclusion criteria
- any suspicious finding of malignant ovarian diseases
- postmenopausal status
- baseline serum AMH < 0.50 ng/mL
- pregnancy
- lactation
- any other endocrine diseases (such as thyroid dysfunction, hyperprolactinemia, or Cushing's syndrome)
- use of hormonal treatments in the 3 months before enrollment
Treatment and study plan
Bipolar coagulation
ProcedurePrimary outcomes
-
Decline rate of serum AMH levels
Time frame: 3 months after therapy
The primary outcome of the study was the impact on ovarian reserve determined by serum AMH levels after the applications of two hemostatic techniques for ovarian wound bleeding.
Sponsors and collaborators
Lead sponsor
CHA University
Other
Registry information
Official study title
Additional Benefit of Hemostatic Sealant in Preserving Ovarian Reserve During Laparoscopic Ovarian Cystectomy: a Randomized Controlled Trial
Important dates
- Study start
- 2012
- Primary completion
- 2013
- Study completion
- 2013
- First posted
- May 20, 2013
- Registry last updated
- Jun 25, 2014
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Related clinical trials
Published trials that share one or more normalized conditions with this study.
Diagnosing Ovarian Cysts - the DOC Study
NCT04188652
Adnexal Diseases, Cysts
Copenhagen, Denmark
View Trial DetailsRisk Factors and Disorders Linked to Uterine Adenomyosis on MRI in Reproductive-Age Women
NCT06697444
Adenomyosis, Adnexal Diseases
Mashhad, Iran
View Trial DetailsPoint of Care 3D Ultrasound for Various Applications: A Pilot Study
NCT02831556
Abdominal Injuries, Adnexal Diseases
Durham, North Carolina, United States
View Trial DetailsOvarian Cyst's Enucleation Spillage Score
NCT05376384
Adnexal Diseases, Cysts
Naples, Italy
View Trial Details